Female Reproductive & Breast

Menopause: symptoms and hormone therapy decisions

Clinical Overview and When to Suspect Menopause

— Median US age 51 (range 45–55); early menopause 40–45; premature ovarian insufficiency (POI) <40

— Perimenopause: menstrual irregularity + vasomotor symptoms beginning a mean of 4 years before final menstrual period (FMP); can last 4–8 years

— Postmenopause: all years after the FMP

— Woman 45+ with hot flashes, night sweats, irregular cycles → diagnosis is clinical; no labs needed

— Woman 40–45 with menopausal symptoms → check FSH, TSH, prolactin, βhCG; consider repeating FSH

— Woman <40 with ≥4 months amenorrhea → workup for POI (FSH ×2, estradiol, karyotype, FMR1 premutation, adrenal antibodies)

— Post-hysterectomy patient with ovaries retained → diagnose by symptoms; FSH unreliable during perimenopause due to variability

— Vasomotor symptoms (VMS): hot flashes, night sweats — affect 75–80%, last median 7–9 years

— Genitourinary syndrome of menopause (GSM): vaginal dryness, dyspareunia, recurrent UTI, urinary urgency — progressive without treatment

— Sleep disturbance, mood lability, depression, cognitive complaints

— Accelerated bone loss (peak 1 year before through 2 years after FMP)

Definition: Menopause = 12 consecutive months of amenorrhea in the absence of other pathologic or physiologic cause, reflecting permanent cessation of ovarian follicular activity.

When to suspect on Step 3:

Symptom domains to anchor your H&P:

Board pearl: In a 48-year-old with classic VMS and irregular cycles, do NOT order FSH — diagnosis is clinical and FSH fluctuates wildly in perimenopause. Ordering it is a distractor answer.

Step 3 management: Frame the visit around (1) symptom severity, (2) cardiovascular/breast/VTE risk stratification, (3) bone health, (4) shared decision-making about hormone therapy (HT) — this scaffold drives every menopause vignette you'll see.

Presentation Patterns and Key History

— Sudden flushing of face/chest/neck, sweating, palpitations lasting 1–5 minutes

— Triggered by warm environments, spicy food, alcohol, stress

— Night sweats disrupt sleep → daytime fatigue, irritability, "brain fog"

— Severity grading drives therapy: mild (tolerable) vs moderate-severe (interfering with sleep/function) — the latter is the indication for systemic HT

— Vaginal dryness, burning, dyspareunia, postcoital bleeding from atrophic mucosa

— Urinary urgency, frequency, dysuria, recurrent UTIs (loss of lactobacilli, pH rise)

— Unlike VMS, GSM is progressive and chronic — does not improve spontaneously

— New-onset or worsening depression risk is 2–4× baseline during perimenopause

— Screen with PHQ-9; do not attribute all mood changes to hormones

— Subjective memory complaints common; objective decline should prompt other workup

— STRAW+10 staging: early transition = variable cycle length (≥7-day difference); late = ≥60-day amenorrhea episodes

— Heavy or prolonged bleeding in perimenopause is NOT normal — evaluate endometrium

— Personal/family history of breast, ovarian, endometrial cancer

— VTE, stroke, MI, CAD risk factors (HTN, DM, smoking, lipids)

— Migraine with aura, active liver disease, unexplained vaginal bleeding

— Time since FMP — critical for the "timing hypothesis"

— Uterus present or absent (determines need for progestogen)

Vasomotor symptoms (VMS) — the dominant complaint:

Genitourinary syndrome of menopause (GSM):

Mood and cognition:

Cycle changes (perimenopause):

Targeted history checklist (drives HT eligibility):

Key distinction: VMS responds dramatically to systemic estrogen; GSM responds to low-dose vaginal estrogen (and systemic only partially). Choosing route based on symptom domain is a frequent Step 3 question.

Board pearl: Any postmenopausal bleeding — even one episode — requires transvaginal ultrasound (endometrial stripe) and/or endometrial biopsy to exclude endometrial cancer.

Physical Exam Findings (and Risk Assessment when relevant)

— BP, HR, BMI, waist circumference — baseline cardiometabolic profile

— Document height annually (loss >1.5 inches suggests vertebral compression)

— Skin: thinning, decreased elasticity, hirsutism if androgen excess present

— Clinical breast exam at the menopause visit; document baseline before initiating HT

— Any dominant mass, skin change, nipple discharge → imaging before HT

— Pale, thin, smooth vaginal mucosa with loss of rugae

— Petechiae, friability, easy bleeding on speculum insertion

— Shortened, narrowed vaginal canal; introital stenosis

— Vaginal pH >4.5 (normal premenopausal ≤4.5) — supports atrophy

— Decreased labial fullness, clitoral hood retraction, urethral caruncle

— Uterus small; ovaries should be non-palpable postmenopausally — a palpable postmenopausal ovary warrants imaging

— Calculate 10-year ASCVD risk (Pooled Cohort Equations)

— Categorize: low <5%, borderline 5–7.5%, intermediate 7.5–20%, high >20%

— Auscultate for bruits; assess peripheral pulses if CV risk elevated

— Kyphosis, height loss → suggest vertebral fracture; order spine imaging

— Document baseline before menopause-related bone loss accelerates

General and vital signs:

Breast exam:

Pelvic exam — classic GSM findings:

Cardiovascular and metabolic assessment (critical for HT decision):

Bone and posture:

Thyroid and neck: palpate thyroid — hyperthyroidism mimics VMS; lymphadenopathy in a woman with bleeding raises malignancy concern.

Step 3 management: Before prescribing systemic HT, document four things: (1) BP <140/90 controlled, (2) breast exam normal + up-to-date mammogram, (3) no unexplained vaginal bleeding, (4) ASCVD risk and VTE risk estimated. Missing any of these is the wrong-answer trap.

Board pearl: A palpable adnexal mass in a postmenopausal woman is ovarian cancer until proven otherwise — order pelvic US and CA-125; do not anchor on menopause symptoms.

Diagnostic Workup — Initial Labs / Imaging

— Age 40–45 with menopausal symptoms: FSH (consider repeating in 4–6 weeks)

— Age <40 with ≥4 months amenorrhea: FSH ×2 separated by ≥4 weeks; if both >25 IU/L (some guidelines >40) → POI

— Post-hysterectomy with intact ovaries and ambiguous symptoms

— FSH is unreliable in perimenopause (fluctuates) and in women on hormonal contraception (suppressed)

— TSH — hyperthyroidism mimics VMS, palpitations, sweats

— βhCG — exclude pregnancy in any reproductive-age amenorrhea

— Prolactin — if galactorrhea or persistent amenorrhea

— CBC, ferritin — fatigue, heavy perimenopausal bleeding

— Fasting glucose/A1c, lipid panel — cardiometabolic baseline before HT

— Karyotype (Turner, mosaicism)

— FMR1 premutation (fragile X — most common heritable cause)

— Adrenal (21-hydroxylase) antibodies for autoimmune POI → screen for adrenal insufficiency

— TPO antibodies (autoimmune thyroid association)

— Transvaginal ultrasound for any postmenopausal bleeding — endometrial stripe >4 mm → biopsy

— Mammogram per USPSTF (biennial 40–74); update before initiating HT

— DXA at age 65 (or earlier with risk factors: FRAX-based, early menopause, glucocorticoids, low BMI, smoking)

Menopause is a CLINICAL diagnosis in women ≥45 with typical symptoms. Routine labs are not indicated to confirm it.

When to order FSH (and what it means):

Rule-out labs for symptom mimics (broad menopause-like presentation):

POI-specific workup (age <40):

Imaging:

Board pearl: AMH (anti-Müllerian hormone) and estradiol levels are not recommended to diagnose menopause — common distractor. AMH is for fertility assessment, not menopausal staging.

Key distinction: In a 38-year-old with amenorrhea, two elevated FSH levels + symptoms = POI, which carries different management (HT until age ~51, fertility counseling, bone/CV surveillance) than natural menopause.

Diagnostic Workup — Advanced or Confirmatory Studies

— Postmenopausal bleeding (any amount): TVUS first

— Endometrial stripe ≤4 mm → observation reasonable if low risk

— Stripe >4 mm, persistent bleeding, or high risk → endometrial biopsy

— Perimenopausal AUB: evaluate per PALM-COEIN; biopsy if age ≥45 or <45 with risk factors (obesity, unopposed estrogen, Lynch, tamoxifen, anovulation, failed medical management)

— Hysteroscopy with directed biopsy if focal lesion suspected on US/SIS

— DXA scan of hip and spine; T-score ≤ −2.5 = osteoporosis; −1.0 to −2.5 = osteopenia

— FRAX 10-year fracture risk to guide therapy in osteopenia

— Secondary osteoporosis labs if osteoporosis at young age: 25-OH vitamin D, calcium, PTH, TSH, 24-hour urinary calcium, SPEP, celiac serologies, testosterone (in men)

— Coronary artery calcium (CAC) score — reclassifies risk for statin and HT decisions

— CAC = 0 in a symptomatic perimenopausal woman strongly supports low CV risk and safety of HT initiation within the timing window

— Personal/family history-driven; routine thrombophilia testing not recommended before HT

— Test only if prior unprovoked VTE, recurrent VTE, or strong family history

— Up-to-date mammogram before HT

— Dense breasts + elevated lifetime risk → consider supplemental screening per shared decision

Endometrial evaluation for abnormal bleeding:

Bone health workup:

Cardiovascular risk refinement (if borderline/intermediate ASCVD):

VTE risk assessment:

Breast imaging:

CCS pearl: When ordering workup for postmenopausal bleeding on CCS, the sequence is pelvic exam → TVUS → endometrial biopsy (or saline infusion sonohysterography/hysteroscopy if focal). Do not start HT or oral contraceptives until malignancy is excluded.

Board pearl: Salivary or serum hormone "panels" marketed for "bioidentical" individualization are not validated — Step 3 will test this as a wrong answer.

Risk Stratification and Treatment Decision Logic

— VMS predominant → systemic therapy candidate

— GSM only → low-dose vaginal estrogen (or DHEA, ospemifene) — no systemic risk

— Both → systemic HT typically covers both

— HT benefits outweigh risks when age <60 OR within 10 years of FMP AND no contraindications

— Initiation >10 years post-FMP or age ≥60 → risks (CHD, stroke, VTE, dementia) outweigh benefits

— History of breast cancer or estrogen-sensitive cancer

— Coronary heart disease, prior MI, stroke/TIA

— Active or prior VTE/PE (unless anticoagulated and risk-benefit favorable)

— Active liver disease

— Unexplained vaginal bleeding

— Pregnancy

— High-risk endometrial cancer

— Migraine with aura (stroke risk)

— Uncontrolled HTN, hypertriglyceridemia (>500)

— Gallbladder disease, elevated VTE risk (obesity, immobility)

— Strong family history of breast cancer or VTE

— Transdermal estrogen preferred over oral in: VTE risk, hypertriglyceridemia, migraine, gallbladder disease, obesity, smoking — bypasses first-pass and does not raise VTE risk

— Oral estrogen acceptable in low-risk women

— Mandatory to prevent endometrial hyperplasia/cancer

— Micronized progesterone preferred (cleanest VTE/breast profile)

— Continuous combined regimen if ≥1 year post-FMP

Step 1 — Identify symptom domain:

Step 2 — Assess HT eligibility ("timing hypothesis"):

Absolute contraindications to systemic HT:

Relative contraindications / cautions:

Step 3 — Choose route:

Step 4 — Add progestogen if uterus present:

Step 3 management: A 52-year-old with severe VMS, BMI 32, and migraine without aura — choose transdermal estradiol + oral micronized progesterone. Choosing oral estrogen in this patient is the wrong answer.

Board pearl: HT is NOT indicated for primary prevention of cardiovascular disease, dementia, or osteoporosis alone — only symptom treatment (with bone protection as a beneficial side effect).

Pharmacotherapy — First-Line Hormone Therapy Regimens

— Transdermal estradiol patch 0.025–0.1 mg/day (preferred if any VTE/CV/metabolic risk)

— Oral estradiol 0.5–2 mg daily; conjugated equine estrogens (CEE) 0.3–0.625 mg

— Vaginal ring (Femring) delivers systemic doses; (Estring is low-dose, local only)

— Start at the lowest effective dose; titrate based on symptom control

— Micronized progesterone 100 mg nightly (continuous) or 200 mg ×12 days/month (cyclic) — first-line, best safety profile

— Medroxyprogesterone acetate 2.5 mg daily — older option, worse lipid/breast signal (WHI used MPA)

— Levonorgestrel IUD — off-label endometrial protection, useful in perimenopause

— Bazedoxifene/CEE (Duavee) — SERM-estrogen combo, no progestogen needed

— Continuous combined (daily estrogen + daily progestogen) → amenorrhea goal; for ≥1 year post-FMP

— Cyclic (estrogen daily + progestogen 12–14 days/month) → predictable monthly bleed; useful in perimenopause

— Estradiol cream, tablet (Vagifem), ring (Estring), or insert (Imvexxy)

— No progestogen needed — minimal systemic absorption

— Safe in most breast cancer survivors after oncology discussion (non-hormonal first; topical estrogen if refractory and not on aromatase inhibitor)

— Paroxetine 7.5 mg (only FDA-approved non-hormonal for VMS) — avoid with tamoxifen (CYP2D6 inhibition)

— Venlafaxine, escitalopram, desvenlafaxine

— Gabapentin 300–900 mg nightly (good for night sweats)

— Fezolinetant (neurokinin-3 receptor antagonist) — newer, monitor LFTs

— Oxybutynin, clonidine (lower tier)

— CBT, weight loss, cooling strategies

Systemic estrogen options:

Progestogen options (uterus intact):

Regimens:

Low-dose vaginal estrogen for GSM (any age, generally safe):

Non-hormonal alternatives for VMS (when HT contraindicated or declined):

Board pearl: Paroxetine + tamoxifen = contraindicated (reduces tamoxifen activation). Use venlafaxine or gabapentin in breast cancer survivors on tamoxifen.

Step 3 management: Duration — reassess annually; no fixed stop date. Continue as long as benefits outweigh risks per shared decision-making.

Expanded Pharmacology and Special Therapy Scenarios

— Treat with HT until average age of menopause (~51) unless contraindicated

— Doses are higher than standard postmenopausal HT (replacing physiologic levels)

— Options: estradiol 100 mcg patch or combined OCP; add cyclic progestogen

— Reduces CV, bone, cognitive, and mortality risks of premature estrogen loss

— Step 1: Non-hormonal vaginal moisturizers (Replens, hyaluronic acid) + lubricants for intercourse

— Step 2: Low-dose vaginal estrogen (cream, tablet, ring) — first-line pharmacotherapy

— Step 3: Vaginal DHEA (prasterone) 6.5 mg insert nightly — alternative

— Step 4: Ospemifene 60 mg PO daily (oral SERM) — for moderate-severe dyspareunia; avoid in breast cancer, VTE history

— Vaginal laser therapy: insufficient evidence, FDA warning — not first-line answer

— HT prevents bone loss and reduces fractures while taken — benefit wanes after discontinuation

— Not first-line for osteoporosis treatment in older women (use bisphosphonates, denosumab)

— In younger postmenopausal women with VMS + low bone mass, HT is a reasonable dual-indication choice

— Not FDA-approved, not regulated for dose accuracy, no safety monitoring

— Marketed with unproven claims of superiority

— Step 3: recommend FDA-approved bioidentical estradiol and micronized progesterone instead — these are bioidentical AND regulated

— Estrogen + CYP3A4 inducers (rifampin, phenytoin, St. John's wort) → decreased efficacy

— Estrogen + thyroid hormone → may need higher levothyroxine dose (increased TBG)

— Estrogen + tamoxifen → contraindicated

Premature ovarian insufficiency (POI) — different paradigm:

Genitourinary syndrome — therapy ladder:

Bone protection:

Tibolone (not available in US) — synthetic steroid with estrogenic, progestogenic, androgenic activity; mentioned for completeness.

Compounded "bioidentical" hormones:

Drug interactions to flag:

Board pearl: Counsel patients that "natural" or "compounded bioidentical" hormones carry the same class risks (VTE, breast, endometrial) as conventional HT, without quality assurance.

Key distinction: Ospemifene treats dyspareunia from GSM; tamoxifen and raloxifene do NOT — and raloxifene may worsen VMS.

Special Populations — Elderly and Renal/Hepatic Impairment

— Do not initiate systemic HT for VMS in this group — risks of stroke, CHD, VTE, and dementia (WHIMS data) outweigh benefits

— Already on HT and tolerating well? Shared decision-making about continuation, lowest effective dose, periodic reassessment — no mandatory stop age

— Persistent VMS in older women: prefer non-hormonal (SSRIs/SNRIs, gabapentin, fezolinetant)

— Low-dose vaginal estrogen remains safe at any age for GSM

— Active liver disease = contraindication to oral estrogen (first-pass metabolism, hepatic protein synthesis effects)

— Transdermal estradiol acceptable in mild stable liver disease — bypasses first-pass

— Monitor LFTs at baseline and periodically; discontinue if cholestasis or transaminitis develops

— Fezolinetant requires LFT monitoring at baseline, months 1, 2, 3, 6, 9 — withhold if ALT/AST >3× ULN

— HT is generally not renally dosed; no specific contraindication in CKD

— Watch for fluid retention with oral estrogen

— Gabapentin (non-hormonal alternative) requires dose adjustment in CKD — eGFR-based titration

— Established CHD, prior MI, prior stroke/TIA → HT contraindicated

— Hypertension: control to <140/90 before initiating; transdermal preferred

— Hypertriglyceridemia >500: oral estrogen can precipitate pancreatitis → use transdermal or avoid

— HT initiation in women ≥65 increased dementia risk (WHIMS) → contraindicated for cognitive prevention

— Do not start HT in women with established dementia

— SSRIs/gabapentin add fall and hyponatremia risk in elderly — Beers criteria caution

— Reassess goals of care; many elderly patients tolerate VMS without pharmacotherapy

Older women (>60 or >10 years post-FMP):

Hepatic impairment:

Renal impairment:

Cardiovascular comorbidity:

Cognitive impairment / dementia:

Polypharmacy and falls (geriatric lens):

Step 3 management: A 68-year-old never on HT with new bothersome VMS — answer is non-hormonal therapy (e.g., low-dose paroxetine or fezolinetant), not new HT initiation, regardless of how severe symptoms appear.

Board pearl: Vaginal estrogen ≠ systemic HT. Age and timing rules do not apply — an 80-year-old with GSM can safely use low-dose vaginal estrogen.

Special Populations — POI, Surgical Menopause, Cancer Survivors

— Causes: idiopathic (most), fragile X premutation (most common identifiable), Turner syndrome, autoimmune polyglandular syndromes, chemo/radiation, oophorectomy

— Adverse outcomes if untreated: osteoporosis, CHD, cognitive decline, mood disorder, sexual dysfunction, increased mortality

— Treat with HT until age ~51 unless contraindicated

— Fertility: spontaneous pregnancy possible in ~5–10% — offer contraception if pregnancy undesired (HT is NOT contraceptive); refer to REI for desired pregnancy (donor oocyte typically required)

— Abrupt, severe symptoms — especially if premenopausal at surgery

— Strongly consider HT until at least age 51 if no contraindication, even if oophorectomy was for BRCA risk reduction (HT does not negate the risk-reduction benefit if uterus and breasts intact and patient is premenopausal)

— Exception: estrogen receptor-positive breast cancer history — generally avoid HT

— Systemic HT contraindicated

— VMS: SSRIs/SNRIs (avoid paroxetine with tamoxifen), gabapentin, fezolinetant, CBT, clonidine

— GSM: non-hormonal first (moisturizers, lubricants); if refractory and not on aromatase inhibitor → low-dose vaginal estrogen with oncology input is generally acceptable; ospemifene contraindicated in active breast cancer

— Low-grade, early-stage: HT may be considered with gyn-onc input

— High-grade or advanced: avoid systemic estrogen

— Avoid systemic HT generally; if essential, transdermal estradiol + micronized progesterone has the lowest VTE signal — only with hematology input

— Avoid oral estrogen (stroke risk); transdermal at lowest dose may be considered

Premature ovarian insufficiency (POI, <40):

Surgical menopause (bilateral oophorectomy):

Breast cancer survivors:

Endometrial cancer survivors:

VTE history:

Migraine with aura:

Board pearl: A 35-year-old woman with new POI is at higher lifetime risk of osteoporosis and CHD than peers — HT is preventive and recommended, opposite of the message for natural menopause at 55.

Key distinction: "Hormone therapy" in POI replaces deficient physiology; "hormone therapy" in postmenopause supplements above natural levels — risk-benefit calculations differ accordingly.

Complications and Adverse Outcomes

— Persistent VMS: sleep disruption, mood disorder, decreased QOL, occupational impairment

— GSM progression: dyspareunia, sexual dysfunction, recurrent UTIs, urinary incontinence

— Accelerated bone loss: 2% trabecular and 1% cortical bone/year for first 5–7 years post-FMP → osteoporotic fracture risk

— Increased visceral adiposity, dyslipidemia, insulin resistance → CV risk acceleration

— POI specifically: premature mortality, dementia, depression if untreated

— VTE: oral estrogen 2–3× baseline risk; transdermal does not increase VTE risk meaningfully

— Stroke: oral estrogen modest increase, especially age >60; transdermal lower risk

— CHD: depends on timing — early initiation neutral/protective; late initiation increases risk

— Breast cancer: combined estrogen-progestogen increases risk after ~5 years (~1 extra case/1000 women/year); estrogen-alone (post-hysterectomy) has neutral or slightly reduced breast cancer risk in WHI

— Endometrial cancer: unopposed estrogen with intact uterus → 5–10× risk → never give estrogen alone to a woman with a uterus

— Gallbladder disease: oral estrogen increases cholelithiasis and cholecystitis

— Ovarian cancer: small absolute increase with long-term use

— Breast tenderness, nausea, headache, bloating, mood changes

— Unscheduled bleeding common in first 6 months of continuous combined regimens; persistent bleeding after 6 months → evaluate endometrium

— SSRIs/SNRIs: sexual dysfunction, hyponatremia, GI, withdrawal

— Gabapentin: sedation, dizziness, falls

— Fezolinetant: hepatotoxicity — monitor LFTs

— Clonidine: orthostasis, dry mouth

Untreated menopause sequelae:

Hormone therapy adverse effects:

Short-term/symptomatic side effects (often improve in 2–3 months):

Non-hormonal therapy adverse effects:

CCS pearl: New unexplained vaginal bleeding on HT → stop HT, TVUS, endometrial biopsy. Do not increase progestogen dose without evaluation.

Board pearl: WHI's breast cancer signal came from CEE + MPA. Modern transdermal estradiol + micronized progesterone may have a more favorable profile, but the class warning still drives counseling.

When to Escalate Care — Referral and Inpatient Triage

— Postmenopausal bleeding with non-diagnostic biopsy or persistent bleeding

— Endometrial hyperplasia (atypical → gyn-onc) or biopsy-proven cancer

— Refractory VMS despite optimized HT and non-hormonal therapy

— Severe GSM not responding to vaginal estrogen

— Suspected adnexal mass or pelvic pathology on exam/imaging

— Complex perimenopausal AUB needing hysteroscopy or ablation

— POI workup and fertility counseling

— Complex hormonal regimens, recurrent treatment failure

— Endometrial cancer or atypical hyperplasia

— Postmenopausal adnexal mass with elevated CA-125 or suspicious imaging

— Lynch syndrome surveillance with menopausal symptoms

— Prior VTE or thrombophilia in a patient strongly desiring HT — risk-benefit and anticoagulation considerations

— Unprovoked VTE while on HT

— Intermediate ASCVD risk where HT decision is uncertain — CAC scoring and risk discussion

— New CV symptoms on HT (chest pain, dyspnea, focal neuro)

— Breast cancer survivors with disabling VMS for tailored non-hormonal plan

— New breast finding while on HT

— Suspected VTE or PE on HT: stop HT immediately, anticoagulate, image (CT-PE, duplex)

— Acute MI or stroke on HT: standard ACS/stroke protocols; discontinue HT

— Heavy vaginal bleeding with hemodynamic instability: IV access, type and cross, gyn consult, possible D&C

— Severe depression with suicidality during perimenopause → psychiatric admission per safety

Gynecology referral:

Reproductive endocrinology referral:

Gynecologic oncology referral:

Hematology referral:

Cardiology referral:

Breast specialist / oncology:

Emergency/inpatient triage (uncommon but board-relevant):

Step 3 management: A perimenopausal woman with new unilateral leg swelling on oral CEE — stop HT, duplex ultrasound, consider empiric anticoagulation if high clinical suspicion (Wells score).

CCS pearl: Whenever you start HT on CCS, schedule a 3-month follow-up for efficacy and adverse effect review — premature closure of the case loses points.

Key Differentials — Same-Category (Endocrine/Reproductive) Causes

— Pregnancy — always check βhCG first, even at 45

— Thyroid disease — hyper- or hypothyroidism alters cycles; TSH

— Hyperprolactinemia — galactorrhea, headache, visual changes → prolactin, MRI pituitary

— PCOS — chronic anovulation, hyperandrogenism, often longstanding; persists into perimenopause

— Hypothalamic amenorrhea — low BMI, athletes, stress; low FSH/LH (vs high in menopause)

— Asherman's syndrome — post-procedure (D&C); normal hormones

— Sheehan's syndrome — postpartum pituitary necrosis; multi-axis hypopituitarism

— Hyperthyroidism — tremor, weight loss, tachycardia, exophthalmos

— Pheochromocytoma — paroxysmal hypertension with sweating, palpitations, headache; plasma metanephrines

— Carcinoid syndrome — flushing + diarrhea + wheeze; 5-HIAA

— Mastocytosis — urticaria, anaphylactoid episodes; serum tryptase

— Medullary thyroid carcinoma — calcitonin

— Diabetic autonomic neuropathy — sweating with hypoglycemia

— Vulvodynia, lichen sclerosus, vaginismus

— Pelvic floor dysfunction

— Endometriosis (typically premenopausal; can persist)

— Pelvic infection, IUD malposition

— Endometrial polyps, submucosal fibroids

— Endometrial hyperplasia/cancer

— Cervical pathology (polyp, cancer)

— Coagulopathy, anticoagulation

— Tamoxifen-induced endometrial changes

Other causes of secondary amenorrhea/oligomenorrhea in midlife:

Other causes of vasomotor-like symptoms:

Other causes of dyspareunia/sexual dysfunction:

Other causes of bleeding:

Board pearl: A 50-year-old with episodic flushing, headache, and BP 180/100 in clinic — don't anchor on menopause; order plasma metanephrines for pheochromocytoma.

Key distinction: Menopause-related VMS has no associated diarrhea, wheeze, or sustained hypertension — those features mandate workup for carcinoid or pheo.

Key Differentials — Other-Category Mimics

— Panic disorder — discrete episodes of palpitations, sweating, sense of doom; DSM-5 criteria; treat with SSRI + CBT

— Generalized anxiety disorder — chronic worry, somatic symptoms

— Major depressive disorder — overlapping fatigue, insomnia, anhedonia; PHQ-9

— PTSD — autonomic arousal, nightmares, hypervigilance

— Paroxysmal atrial fibrillation/SVT — palpitations without flushing; ECG, Holter, event monitor

— Angina equivalents — diaphoresis with exertion; rule out ACS in at-risk patient

— Orthostatic intolerance/POTS — younger women, postural symptoms

— Tuberculosis — night sweats, weight loss, cough; B symptoms

— Lymphoma/leukemia — night sweats, weight loss, lymphadenopathy; check CBC, LDH

— Endocarditis — fevers, night sweats, murmur

— HIV — night sweats, lymphadenopathy

— Brucellosis, malaria, occult abscess in appropriate exposure history

— Tamoxifen, aromatase inhibitors — induce VMS

— GnRH agonists (leuprolide for fibroids, endometriosis, breast cancer)

— SSRIs — paradoxical sweating

— Niacin — flushing

— Calcium channel blockers — flushing

— Opioid withdrawal — sweats, anxiety

— Alcohol use disorder / withdrawal

— Alcohol flush

— Stimulants, cocaine

— Caffeine excess

— Obstructive sleep apnea — night sweats, fatigue, mood — screen with STOP-BANG

— Hyperhidrosis (primary) — focal, not flushing

— Diabetic hypoglycemia — sweats with neuroglycopenia

Psychiatric:

Cardiovascular:

Infectious/systemic:

Medication-induced:

Substance-related:

Other:

Step 3 management: A 55-year-old woman with night sweats, 10-pound weight loss, and cervical lymphadenopathy — night sweats here are a B symptom, not menopause — work up lymphoma (CBC, LDH, imaging, biopsy).

Board pearl: Three classic features that distinguish non-menopausal night sweats: weight loss, lymphadenopathy, and drenching sweats requiring bedding/clothing change. Investigate.

Secondary Prevention / Long-Term Care Plan

— BP to <130/80 (or <140/90 per indication); lifestyle + pharmacotherapy

— Lipids: statin per ASCVD risk; consider CAC if borderline

— Diabetes: A1c screening every 3 years from 35 (USPSTF) or annually if prediabetes

— Tobacco cessation — single highest-yield intervention

— Weight, physical activity — 150 min/week moderate aerobic + 2 days resistance

— Mediterranean or DASH diet

— Aspirin: NOT for primary prevention in most; individualize age 40–59 with ASCVD ≥10% and low bleeding risk

— Calcium 1200 mg/day (diet preferred) and vitamin D 600–800 IU/day

— Weight-bearing and resistance exercise

— DXA at 65 (or earlier with risks); repeat per T-score

— Osteoporosis treatment: bisphosphonates first-line; denosumab, romosozumab, teriparatide per risk

— Fall prevention assessment annually after 65

— Breast: mammogram biennially 40–74 (USPSTF 2024); shared decision after 75

— Cervical: cytology + HPV per ACS/USPSTF; stop at 65 if adequate prior negative screening

— Colorectal: start at 45; colonoscopy q10y or alternatives

— Lung: LDCT 50–80 if ≥20 pack-years and currently smoking or quit within 15 years

— Annual depression and anxiety screening (PHQ-2/PHQ-9, GAD-7)

— Sleep hygiene, screen for OSA

— Social connection, cognitive engagement

— Address GSM proactively; discuss intimacy, partner factors

— STI screening per risk; HIV at least once 15–65

— Influenza annual; COVID-19 per current guidance

— Tdap booster q10y

— Zoster (Shingrix) ≥50; pneumococcal ≥65 (or earlier with comorbidities); RSV per age/risk

Cardiovascular disease prevention (leading cause of death in postmenopausal women):

Bone health:

Cancer screening (Step 3 staples):

Mental health and cognition:

Sexual health:

Immunizations:

Step 3 management: The menopause visit is a prime opportunity to consolidate preventive care — the right answer often pairs symptom management with one age-appropriate screening or vaccination.

Follow-Up, Monitoring, and Counseling Cadence

— 6–8 weeks after starting: symptom response, side effects, adherence, unscheduled bleeding

— 3 months: dose titration, BP, weight; confirm symptom control

— Annually thereafter: reassess indication, risks, breast exam, mammogram status, BP, lipids, ASCVD risk

— Is the indication (moderate-severe VMS) still present?

— Any new contraindications (VTE, CV event, breast cancer)?

— Lowest effective dose?

— Is non-hormonal therapy now reasonable?

— Mammogram up to date?

— Any unscheduled bleeding?

— Cyclic regimen: expected withdrawal bleed; investigate heavy/prolonged bleeding

— Continuous combined: irregular bleeding common first 6 months; persistent bleeding beyond 6 months → TVUS ± biopsy

— DXA every 2 years if osteopenia or on therapy; less frequent if normal

— Reassess fracture risk with FRAX

— BP at every visit; lipids per ACC/AHA cadence

— Annual A1c if prediabetic; q3y if normal

— No mandatory duration limit; periodic trial discontinuation reasonable

— Taper vs abrupt stop: both acceptable; tapering may reduce symptom rebound (no strong evidence)

— VMS may recur in ~50% on stopping; counsel and offer non-hormonal bridge if needed

— Symptoms are time-limited but median duration ~7–9 years

— HT is the most effective treatment for VMS — risks are real but small in absolute terms when initiated within the window

— Lifestyle (weight, alcohol moderation, sleep hygiene, layered clothing, trigger avoidance, exercise) helps

— Non-hormonal options exist and are effective

— Compounded "bioidenticals" are not safer — avoid

Initial HT follow-up:

Annual HT review checklist:

Bleeding monitoring:

Bone health monitoring:

Cardiometabolic monitoring:

Discontinuation strategy:

Counseling content (shared decision-making — heavily tested):

Board pearl: At the annual visit, document shared decision-making explicitly (risks, benefits, alternatives, patient preference) — Step 3 favors answers that include re-counseling rather than autopilot refills.

CCS pearl: When you start HT, also order: BP check at 6 weeks, repeat lipids in 3 months, schedule mammogram if due. Bundling preventive care is the high-yield CCS move.

Ethical, Legal, and Patient Safety Considerations

— Document discussion of risks (VTE, stroke, breast cancer with combined regimens, gallbladder), benefits (VMS control, GSM, bone), alternatives (non-hormonal, lifestyle, no treatment), and patient values/preferences

— Use teach-back — many patients overestimate HT cancer risk from media

— Re-document consent at annual review or when changing regimen — preferences evolve

— Patient may request HT despite a relative contraindication (e.g., strong breast cancer family history)

— Patient may refuse HT despite severe symptoms — respect autonomy; offer non-hormonal

— Document the conversation; do not coerce in either direction

— Counsel against unregulated compounded preparations and pellet therapy

— Marketing claims of "individualized" salivary-tested regimens are not evidence-based

— Physicians prescribing under patient pressure should still document evidence-based counseling

— A woman discharged from gynecology on HT needs primary care handoff with: indication, regimen, contraindications, monitoring plan, mammogram and DXA cadence

— POI patients transitioning from adolescent/REI care to adult primary care need explicit education on continued HT until ~51, bone/CV surveillance, fertility status

— Hospital discharge after VTE on HT: clear instruction to stop HT and outpatient hematology follow-up; reconcile medication list

— Sexual dysfunction, intimate partner violence (increases in midlife transitions) — screen privately

— Adolescent/young adult with POI: psychological impact of infertility — refer for counseling

— Estrogen monotherapy in a woman with intact uterus = endometrial cancer risk → never omit progestogen

— Failure to evaluate postmenopausal bleeding → delayed cancer diagnosis (medicolegal high-risk)

— Continuing HT after a new CV event → preventable harm; medication reconciliation at every encounter

— Drug interactions (tamoxifen + paroxetine) — pharmacy review

— Women of color are undertreated for VMS despite higher symptom burden — actively offer therapy and screen for bias

Informed consent for hormone therapy:

Shared decision-making with conflicting evidence:

Compounded "bioidentical" hormones — ethical duty:

Transitions of care (Step 3 favorite):

Confidentiality and sensitive topics:

Patient safety pitfalls:

Health equity:

Step 3 management: A patient on combined HT presents to ED with PE — the discharge plan must explicitly include HT discontinuation, anticoagulation, and PCP follow-up within 1–2 weeks; failure to communicate this is a transitions-of-care error.

High-Yield Associations and Rapid-Fire Facts

Hormonal hallmarks of menopause: FSH ↑↑, LH ↑, estradiol ↓; inhibin B ↓ → loss of negative feedback

STRAW+10 staging is the standard framework — late reproductive → early/late transition → early/late postmenopause

Average age of natural menopause: 51 in US; smoking advances by ~2 years

POI definition: menopause <40 with elevated FSH ×2

Most common identifiable cause of POI: FMR1 (fragile X) premutation

Vaginal pH >4.5 = atrophy / GSM

Endometrial stripe >4 mm with postmenopausal bleeding → biopsy

Unopposed estrogen + intact uterus = endometrial hyperplasia/cancer

Transdermal estrogen does NOT increase VTE risk (unlike oral)

Micronized progesterone = preferred progestogen (best safety profile)

WHI key results: CEE+MPA increased breast cancer, CHD (older women), stroke, VTE; CEE alone (hysterectomized) had neutral/lower breast cancer

Timing hypothesis: initiating HT <60 or within 10 years of FMP = favorable; later = harmful

Only FDA-approved non-hormonal for VMS: paroxetine 7.5 mg

Fezolinetant = NK3 receptor antagonist; LFT monitoring required

Paroxetine + tamoxifen = contraindicated (CYP2D6)

Ospemifene = oral SERM for moderate-severe dyspareunia

Vaginal estrogen is safe at any age; minimal systemic absorption; no progestogen needed

Bone loss peaks 1 year before through 2 years after FMP

DXA at 65 routinely; earlier with FRAX risk

HT is not first-line for osteoporosis treatment (use bisphosphonates) but is acceptable in younger postmenopausal women with VMS + osteopenia

Breast cancer survivor + VMS: SSRI/SNRI (not paroxetine if on tamoxifen), gabapentin, fezolinetant, CBT

Surgical menopause is more severe than natural — strongly consider HT until age 51

Hot flashes triggers: alcohol, caffeine, spicy food, stress, warm environments

Postmenopausal bleeding = cancer until proven otherwise

Cardiovascular disease is the #1 cause of death in postmenopausal women — prevention focus

Compounded bioidenticals are not safer or better — counsel against

Smoking worsens VMS, bone loss, and CV risk — cessation is highest-yield

Sleep apnea prevalence rises postmenopausally — screen if fatigue, night sweats, snoring

Board pearl: When the stem says "55-year-old with VMS, hysterectomy 5 years ago" → answer is estrogen alone (no progestogen needed).

Board Question Stem Patterns

— Best initial therapy: systemic HT (transdermal or oral estradiol + micronized progesterone)

— Distractors: FSH level (no), bioidentical compounded therapy (no), SSRI (second-line)

— Answer: non-hormonal — paroxetine, venlafaxine, gabapentin, or fezolinetant

— Answer: low-dose vaginal estrogen (no progestogen, no systemic risk)

— Answer: endometrial biopsy + add progestogen; this regimen was inappropriate

— Answer: TVUS (stripe >4 mm → endometrial biopsy)

— Answer: start HT until age 51; check FMR1, karyotype, adrenal antibodies; counsel on fertility

— Answer: do not initiate HT; offer non-hormonal therapy (low-dose paroxetine, fezolinetant)

— Answer: venlafaxine or gabapentin (avoid paroxetine — CYP2D6 inhibition of tamoxifen)

— Answer: CBC, LDH, chest imaging, biopsy — workup lymphoma, not menopause

— Answer: HT until age 51 unless contraindicated; doesn't negate risk-reduction benefit

— Answer: transdermal estradiol + micronized progesterone (lowest VTE risk regimen)

Stem 1 — Classic VMS: 52-year-old with 6 months of hot flashes, night sweats disrupting sleep, last menses 14 months ago. BP 124/78, BMI 26, no contraindications.

Stem 2 — Contraindication to HT: 54-year-old with VMS and history of DVT 3 years ago on OCPs.

Stem 3 — GSM only: 60-year-old with dyspareunia and recurrent UTIs; no VMS; vaginal exam shows pale, thin mucosa.

Stem 4 — Unopposed estrogen trap: 50-year-old started on oral CEE alone; intact uterus; now with vaginal bleeding.

Stem 5 — Postmenopausal bleeding: 58-year-old with one episode of spotting 2 years after FMP.

Stem 6 — POI: 32-year-old with 6 months amenorrhea, hot flashes, FSH 55 on two occasions.

Stem 7 — Timing hypothesis: 67-year-old, never on HT, asks about starting for VMS.

Stem 8 — Breast cancer survivor on tamoxifen with VMS:

Stem 9 — Mimic: 50-year-old with night sweats, 15-lb weight loss, palpable cervical node.

Stem 10 — Surgical menopause: 42-year-old s/p BSO for BRCA risk reduction, severe VMS.

Stem 11 — VTE risk reduction approach: 53-year-old, BMI 34, migraine without aura, severe VMS.

Step 3 management: Common wrong answers across stems — checking FSH in typical menopause, compounded bioidenticals, estrogen alone with intact uterus, HT initiation in elderly, paroxetine with tamoxifen.

One-Line Recap

Menopause is a clinical diagnosis in women ≥45 with vasomotor and genitourinary symptoms; systemic hormone therapy is the most effective VMS treatment when initiated in healthy women under 60 or within 10 years of the final menstrual period, with transdermal estradiol plus micronized progesterone (if uterus present) being the safest regimen, while low-dose vaginal estrogen safely treats GSM at any age and non-hormonal options (paroxetine, venlafaxine, gabapentin, fezolinetant) serve patients with contraindications.

Decision framework: identify symptom domain (VMS vs GSM vs both) → assess HT eligibility (timing hypothesis, contraindications, ASCVD/VTE/breast risk) → choose route (transdermal preferred if any risk) → add progestogen if uterus present → reassess annually with shared decision-making.

Never-miss safety items: (1) any postmenopausal bleeding demands TVUS ± biopsy before attributing to HT or atrophy; (2) never give unopposed estrogen to a woman with a uterus; (3) do NOT initiate systemic HT in women >60 or >10 years post-FMP — use non-hormonal; (4) paroxetine + tamoxifen is contraindicated; (5) POI patients need HT until ~51 to prevent premature CV, bone, and cognitive complications.

Highest-yield Step 3 pearls: diagnosis is clinical (don't order FSH at 50); transdermal estrogen does not raise VTE risk; vaginal estrogen is safe at any age and needs no progestogen; surgical menopause and POI carry different (more aggressive) treatment imperatives than natural menopause; menopause visits are a prime opportunity to consolidate preventive care (mammogram, DXA, lipids, immunizations, cancer screening, depression screening).

Counseling north star: HT is symptom therapy, not disease prevention — individualize, document shared decision-making, use the lowest effective dose for the shortest needed duration, and reassess annually with the patient's evolving values, comorbidities, and life context.